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ORIGINAL ARTICLE BACTERIOLOGYHigh-level quinolone resistance is associated with the overexpression of
smeVWX in Stenotrophomonas maltophilia clinical isolatesG. García-León1, C. Ruiz de Alegría Puig2, C. García de la Fuente2, L. Martínez-Martínez2,3, J. L. Martínez1 and M. B. Sánchez1
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Marqués de Valdecilla-IDIVAL, Avda. Valdecilla s/n and 3) Department of Molecular Biology, University of Cantabria, Cardenal Herrera Oria, s/n, Santander, SpainAbstractStenotrophomonas maltophilia is the only known bacterium in which quinolone-resistant isolates do not present mutations in the genes
encoding bacterial topoisomerases. The expression of the intrinsic quinolone resistance elements smeDEF, smeVWX and Smqnr was
analysed in 31 clinical S. maltophilia isolates presenting a minimum inhibitory concentration (MIC) range to ciproﬂoxacin between 0.5 and
> 32 μg/mL; 11 (35.5%) overexpressed smeDEF, 2 (6.5%) presenting the highest quinolone MICs overexpressed smeVWX and 1 (3.2%)
overexpressed Smqnr. Both strains overexpressing smeVWX presented changes at the Gly266 position of SmeRv, the repressor of
smeVWX. Changes at the same position were previously observed in in vitro selected S. maltophilia quinolone-resistant mutants, indicating
this amino acid is highly relevant for the activity of SmeRv in repressing smeVWX expression. For the ﬁrst time SmeVWX
overexpression is associated with quinolone resistance of S. maltophilia clinical isolates.
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csic.es (M.B. Sánchez)Stenotrophomonas maltophilia is an opportunistic pathogen [1,2]
that presents low susceptibility to antibiotics [3], likely because
it harbours several chromosomally encoded resistance de-
terminants, including efﬂux pumps, antibiotic-inactivating en-
zymes and the quinolone resistance protein SmQnr [4–8]. In
addition, S. maltophilia is the only known bacterium in which
quinolone resistance has not been associated with mutations in
genes encoding bacterial topoisomerases [9–11]. Some work
has shown that overexpression of the efﬂux pump SmeDEF
correlates with quinolone resistance of in vitro selected mutants
[11], and several clinical S. maltophilia isolates overexpress thisMicrobiol Infect 2015; 21: 464–467
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.01.007pump [12–15]. In vitro work also shows that S. maltophilia
quinolone resistance also may be due to the overexpression of
another efﬂux pump, SmeVWX [11], although nothing is known
about the selection of this resistance mechanism in clinical
isolates. Another unexplored possibility that might be involved
in the acquisition of resistance by S. maltophilia clinical isolates
could be SmQnr overexpression.
To ascertain the role that these resistance determinants may
have in the in vivo acquisition of S. maltophilia quinolone resis-
tance, we studied the susceptibility to quinolones and the
expression of smeDEF, smeVWX and Smqnr in a collection of 31
S. maltophilia clinical strains, isolated at the Hospital Uni-
versitario Marqués de Valdecilla, Santander (Spain). The strains
were identiﬁed by MicroScan (Siemens Healthcare, Erlangen,
Germany) and API 20NE (BioMérieux, Marcy l’Etoile, France)
and their identiﬁcation as S. maltophilia was further conﬁrmed
by species-speciﬁc polymerase chain reaction (PCR) [16] and by
sequencing the 16S rRNA gene using PA[B27F] and PLO6-R
primers [17]. To discard widely distributed clones that mightious Diseases. Published by Elsevier Ltd. All rights reserved
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was determined by repetitive element palindromic PCR [18].
Although some strains such as 452 and 3759 present a similar
electrophoretic proﬁle, the collection is not biased by the
presence of predominant clones (Fig. 1).
Minimum inhibitory concentrations (MICs) were determined
by Etest (BioMérieux, Marcy l’Etoile, France) using Mueller Hin-
ton agar (Pronadisa, Madrid, Spain). S. maltophilia D457 (19) and
two of its isogenic mutants, D457R [7,19] (which overexpresses
smeDEF) and MBS287 (which overexpresses smeVWX) [11],
were used as controls. RNA was obtained as described [11].
SmeDEF extrudes chloramphenicol, tetracycline and quino-
lones [7]. Consistent with a potential SmeDEF overexpression,
several strains presented lower levels of susceptibility to these
antibiotics than the control strain D457 (Table 1). To study this
possibility, smeD expression was analysed in the 31 clinical
strains by RT-PCR with one-step reaction Illustra Ready-to-Go
RT-PCR Beads Kit (GE Healthcare, Freiburg, Germany) using
primers 1/2 for smeD [15] and FtsZ1/FtsZ2 for the referenceFIG. 1. Analysis of the phylogenetic
relationship of the studied
S. maltophilia clinical isolates. The
phylogenetic relationship of the
strains was determined by analysing
the band patterns obtained by repet-
itive element palindromic polymerase
chain reaction. The electrophoretic
proﬁles were analysed using FPQuest
II software version 4.5 (BioRad). As
shown in the ﬁgure, although some
isolates presented similar patterns,
there were not predominant clones
in the studied strains.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologygene ftsZ [11]; 35.5% (11 of 31) of the strains overexpressed
smeD. We have previously shown that expression of the outer
membrane protein of SmeDEF, SmeF, correlates with the
expression of smeD RNA [7,15]. In other words, expression of
SmeDEF at the protein level correlates with its expression at
the RNA level. To further conﬁrm our results, the expression
of SmeF was analysed using speciﬁc antibodies as described [7].
The same 11 strains overexpressing smeD overexpressed SmeF
(Table 1). These data agree with previous information, showing
that SmeDEF overexpression is frequent in clinical S. maltophilia
isolates [12–15]. The fact that other isolates such as 6632 or
7274 (Table 1) also present low susceptibility to quinolones
without overexpressing SmeDEF indicates that other quinolone
resistance mechanisms must be acting.
In vitro selected quinolone-resistant mutants may present
increased smeVWX expression [11]. To decipher whether this
novel mechanism of quinolone resistance is selected in clinical
S. maltophilia isolates, the level of smeW expression was ana-
lysed in the 31 clinical strains by quantitative reverseand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 464–467
TABLE 1. Antibiotic susceptibilities and expression of efﬂux pumps smeDEF and smeVWX of S. maltophilia clinical strains
MIC (μg/mL) Overexpression*
Strain Origin NAL CIP MOX TET CHL smeVWX smeDEF
2057 Sputum >256 >32 >32 >256 24 + −
6775 Sputum >256 >32 >32 4 >256 + −
205 Urine >256 2 0.125 >256 96 − +
1254 Tracheal aspirate 64 1.5 0.250 96 12 − +
2218 Sputum 48 2 0.250 24 8 − +
4349 Surgical wound exudate 48 6 0.125 >256 64 − +
4377 Skin ulcer 32 3 0.19 >256 24 − +
391 Skin ulcer 32 2 0.125 >256 192 − +
6613 Surgical wound exudate 24 0.75 0.064 >256 16 − +
4378 Diabetes foot exudate 16 0.75 0.064 >256 32 − +
5020 Blood culture 12 1 0.125 >256 24 − +
4076 Sputum 8 1 0.094 24 12 − +
311 Tracheal aspirate 8 0.5 0.032 24 16 − +
7274 Urine >256 6 0.5 >256 8 − −
6632 Skin ulcer >256 6 0.125 >256 32 − −
724 Sputum 96 1.5 0.125 >256 32 − −
7424 Diabetes foot exudate 48 3 0.094 >256 24 − −
3759 Sputum 32 1 0.125 32 4 − −
6521 Sputum 32 1 0.125 >256 8 − −
4399 Articular biopsy 32 1.5 0.125 >256 16 − −
927 Brain biopsy 24 0.5 0.023 >256 4 − −
786 Blood culture 24 1.5 0.094 >256 32 − −
3225 Surgical wound exudate 16 1 0.064 12 3 − −
823 Bronchoalveolar lavage 16 3 0.5 64 8 − −
4515 Surgical wound exudate 16 2 0.5 >256 12 − −
4817 Surgical wound exudate 12 0.75 0.064 32 16 − −
2166 Urine 8 0.75 0.094 32 4 − −
452 Pleural ﬂuid 8 0.5 0.032 >256 12 − −
584 Surgical wound exudate 8 0.75 0.064 24 48 − −
5973 Sputum 4 0.75 0.047 64 4 − −
6250 Abdominal drainage 3 0.5 0.064 32 2 − −
D457 Bronchial aspirate 12 1.5 0.190 6 4 − −
D457R D457 mutant in smeT 128 >32 0.750 48 96 − +
MBS287 D457 mutant in smeRv >256 >32 0.750 6 >256 + −
NAL, nalidixic acid; CIP, ciproﬂoxacin; MOX, moxiﬂoxacin; TET, tetracycline; CHL, chloramphenicol.
*Efﬂux pump with (+) or without (−) overexpression.
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and 6775, which present the highest MICs to quinolones
(Table 1), showed higher levels of smeVWX expression than
our control strain D457 (fold changes 2.65 ± 0.79 and
19 ± 10.66, respectively). To the best of our knowledge this is
the ﬁrst time that overexpression of smeVWX has been asso-
ciated with high-level quinolone resistance in S. maltophilia
clinical strains. In vitro selected S. maltophilia mutants over-
expressing smeVWX contain mutations in the gene encoding the
repressor of the pump, smeRv [11]. Consequently, the smeRv
alleles from 2057 and 6775 were PCR-ampliﬁed and sequenced
as described [11]. Both isolates presented mutations at smeRv in
comparison with the sequence of the wild-type allele of the
control strain D457; 2057 presented one Gly266Ser mutation,
whereas 6775 presented three mutations: Gly46Asp,
Thr222Pro and Gly266Asp. The mutations at positions Gly266,
Gly266Ser and Gly266Asp have been described previously in
mutants obtained in vitro [11]. Together with our results, it
indicates that this amino acid is relevant for SmeRv activity. This
substitution of glycine for serine or aspartic acid results in
smeVWX overexpression and consequently high-level quino-
lone resistance in S. maltophilia.
Five of the studied strains presented nalidixic acid MICs
>256. Two of them (2057 and 6775) overexpressed smeVWX,Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectand another (205) overexpressed smeDEF. In addition to
SmeDEF and SmeVWX, S. maltophilia encodes in its genome six
RND efﬂux pumps, SmeABC, SmeGH, SmeIJK, SmeMN,
SmeOP and SmeYZ [4]. To determine whether the high-level
resistance to quinolones observed in strains 7274 and 6632
was due to the overexpression of any of these efﬂux pumps,
their level of expression was analysed by RT-qPCR as described
[20]. None of these pumps was overexpressed in strains
7274 and 6632. Although it has been reported that
S. maltophilia–resistant mutants do not present mutations in the
genes encoding bacterial topoisomerases, it would be possible
that this type of mutations could be responsible for the resis-
tance of strains 7274 and 6632. To address this possibility, the
quinolone resistance determining regions (QRDRs) of the
topoisomerase genes (gyrA, gyrB, parC and parE) were ampliﬁed
and sequenced in the strains 7274 and 6632, as described [21].
In agreement with previous studies [9,21], we did not ﬁnd
signiﬁcant mutations in the studied QRDRs.
Irrespective of efﬂux pumps, the deletion of Smqnr has been
reported to increase quinolone susceptibility in S. maltophilia,
whereas its overexpression under control of a heterologous
promoter in a plasmid reduces such susceptibility [22]. Smqnr
expression was analysed in the 31 clinical isolates by RT-qPCR
as described [22] using primers RTqnr7 (50ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 464–467
CMI García-León et al. Role of SmeVWX on S. maltophilia quinolone resistance 467AGTGGTCGACCAGCAGTTC 30) and RTqnr8 (50 CATCG-
TAGAAGCTGCAGTTGATG 30). Only S. maltophilia 6775
showed higher Smqnr expression than our wild-type control
strain D457 (2.4 ± 0.2). Because 6775 also overexpresses
SmeVWX, it is difﬁcult to evaluate the role that Smqnr over-
expression may have in the high-level quinolone resistance of
this isolate. These results are in agreement with studies on
in vitro selected S. maltophilia quinolone-resistant mutants; none
of which presented increased Smqnr expression [11].
Our data indicate that overexpression of the efﬂux pumps
SmeDEF or SmeVWX is frequent in clinical isolates of
S. maltophilia, whereas overexpression of the chromosomally
encoded Qnr protein SmQnr does not seem to be a relevant
mechanism for the acquisition of quinolone resistance in the
studied isolates. To the best of our knowledge this is the ﬁrst
study reporting that overexpression of efﬂux pump smeVWX,
due to mutations in its regulator SmeRv, is associated with
high-level quinolone resistance in S. maltophilia clinical
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